What is Maroteaux–Lamy Syndrome
Maroteaux–Lamy syndrome, also known as arylsulfatase B deficiency or mucopolysaccharidosis type VI (MPS VI), is a rare inherited lysosomal storage disorder. It results from insufficient activity of the enzyme arylsulfatase B, which leads to accumulation of glycosaminoglycans in cells and tissues. This accumulation can affect skeletal structure, organ function, and mobility over time. The condition is typically inherited in an autosomal recessive pattern. People living as a Maroteaux–Lamy syndrome survivor often work with a multidisciplinary care team to manage symptoms and maintain quality of life.
Key Clinical Features and Presentation
Signs of MPS VI usually become apparent in childhood and may progress slowly. Common features include coarse facial features, corneal clouding, joint stiffness, and enlarged abdomen due to organomegaly. Growth may be slower than peers, and some individuals develop joint contractures over time. The level of intellectual function varies; many have normal cognitive ability, while others may experience mild learning challenges. Because manifestations can differ widely, care is often tailored to the individual’s specific needs.
Physical Characteristics
- Coarse facial features, including a broad nose and thick lips
- Corneal clouding that may affect vision
- Joint stiffness and reduced mobility
- Enlarged liver and spleen (hepatosplenomegaly)
- Short stature relative to family growth patterns
Disease Progression and Variability
MPS VI is a progressive condition, but the rate and pattern of progression vary widely. Some individuals remain mobile and independent into adulthood, while others may experience more pronounced skeletal or respiratory challenges. Regular monitoring and early intervention can help slow functional decline and address complications promptly.
Diagnosis and Testing Approaches
Diagnosis typically begins with urine tests that detect excess glycosaminoglycans, followed by specific enzyme assays to measure arylsulfatase B activity. Genetic testing can confirm mutations in the ARSB gene. Newborn screening programs in some regions include MPS disorders, which can support earlier identification. Accurate diagnosis enables timely planning for supportive care and treatment.
Management and Treatment Options
Management of Maroteaux–Lamy syndrome focuses on symptom relief, preserving function, and preventing complications. Treatment may include enzyme replacement therapy, which can reduce substrate accumulation in some individuals, as well as physical therapy to maintain joint mobility. Respiratory support, pain management, and surgical interventions may be considered based on severity.
Common Interventions
| Approach | Purpose | Notes |
|---|---|---|
| Enzyme replacement therapy | Reduce glycosaminoglycan buildup | May improve joint mobility and respiratory parameters |
| Physical and occupational therapy | Maintain range of motion and function | Tailored to individual tolerance and needs |
| Respiratory support | Manage sleep apnea and airway clearance | May include medications or devices |
| Surgical procedures | Address structural complications | Examples: spinal stabilization, corneal transplant in select cases |
Daily Living and Long-Term Outlook
Many individuals with MPS VI lead meaningful, active lives with appropriate support. Education plans, workplace accommodations, and assistive devices can enhance independence. Lifespan varies, and ongoing advances in treatment continue to improve outcomes. A Maroteaux–Lamy syndrome survivor often emphasizes proactive monitoring, adaptive strategies, and strong support networks as central to long-term well-being.
Support and Care Coordination
Effective care typically involves endocrinologists, geneticists, physiotherapists, ophthalmologists, and other specialists. Families and survivors can benefit from connecting with patient advocacy organizations, peer support groups, and mental health resources. Coordinated care helps align medical, educational, and social goals over time.
Conclusion
Understanding Maroteaux–Lamy syndrome as a survivable condition has evolved with advances in diagnosis and therapy. While challenges persist, many survivors maintain fulfilling routines and achieve key life milestones. Continued research and personalized care remain vital to sustaining function and improving quality of life for those affected.